All In Biotech

Drug Trial Radar · NCT06596252

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Double-blind, Randomized, Non-inferiority Phase III Trial on the Efficacy and Tolerability of 2 mg Once Daily vs. 1 mg Twice Daily Budesonide Orodispersible Tablets in Adults With Eosinophilic Esophagitis

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 308 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

308

Planned (sponsor's estimate)

Start

May 21, 2021

Primary completion

Dec 2026

Study completion Mar 2028

Sponsor

Lead sponsor
Dr. Falk Pharma GmbHIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.

Conditions

  • Eosinophilic Esophagitis

Interventions

  • BudesonideDrug

    Twice daily intake of the tablet 30 min after a meal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients in histological remissionTime frame: 6 weeks

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Dr. Falk Investigational Site

    Scottsdale, Arizona

  • Dr. Falk Investigational Site

    Little Rock, Arkansas

  • Dr. Falk Investigational Site

    La Jolla, California

  • Dr. Falk Investigational Site

    San Diego, California

  • Dr. Falk Investigational Site

    Doral, Florida

  • Dr. Falk Investigational Site

    New Port Richey, Florida

  • Dr. Falk Investigational Site

    Boise, Idaho

  • Dr. Falk Investigational Site

    Boston, Massachusetts

  • Wyoming

    Ann Arbor, Michigan

  • Dr. Falk Investigational Site

    Wyoming, Michigan

  • Dr. Falk Investigational Site

    Rochester, Minnesota

  • Dr. Falk Investigational Site

    Freehold, New Jersey

  • Dr. Falk Investigational Site

    New York, New York

  • Dr. Falk Investigational Site

    Chapel Hill, North Carolina

  • Dr. Falk Investigational Site

    Cleveland, Ohio

  • Dr. Falk Investigational Site

    Mentor, Ohio

  • Wyoming

    Philadelphia, Pennsylvania

  • Dr. Falk Investigational Site

    Harlingen, Texas

  • Dr. Falk Investigational Site

    Salt Lake City, Utah

  • Dr. Falk Investigational Site

    Lynchburg, Virginia

  • Department of Gastroenterology, Hospital General de Tomelloso

    Tomelloso, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.